Ep 1: Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were…

Peptides Weekly · Sep 23, 2026 · 6m · transcript

Peptides Weekly Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were released this week. What You Need to Know: Novo Nordisk reported new phase 3 data on an amylin-based candidate. A pair of randomized trials found oral semaglutide did not slow progression in mild Alzheimer’s disease. ... AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.